medigraphic.com
Centro Universitario de Ciencias de la Salud de la Universidad de Guadalajara y del OPD Hospitales Civiles de Guadalajara

2005, Número s1

<< Anterior Siguiente >>

Inv Salud 2005; 7 (s1)


Esteatohepatitis no alcohólica

Martínez LE, Domínguez RJA, Hernández NZH, Panduro CA

Idioma: Español
Referencias bibliográficas: 67
Paginas: 40-47
Archivo PDF: 223.05 Kb.


RESUMEN

En 1980 Ludwing y col. describieron pacientes sin antecedentes de consumo de alcohol que mostraban resultados en la biopsia hepática no distinguibles de la hepatitis alcohólica, acuñándose entonces el término “esteatohepatitis no alcohólica” (EHNA). Los criterios de diagnóstico propuestos por Powell en 1990 para EHNA describen que la biopsia hepática debe presentar degeneración grasa macrovesicular con presencia de inflamación, sin antecedentes de consumo de alcohol y descartar infecciones por virus de hepatitis B y C. La prevalencia de EHNA en la población general no ha sido definida actualmente, pero se ha reportado que aproximadamente del 1.2 al 9% de los pacientes con biopsia hepática la presentan. Se cree que esta cifra aumentará significativamente en pacientes asintomáticos. La anormalidad frecuentemente observada en estos sujetos es la elevación plasmática de las enzimas hepáticas. La EHNA se presenta principalmente en mujeres y se asocia a enfermedades metabólicas: resistencia a la insulina, obesidad, DM2 e hiperlipidemias. La patogénesis de EHNA no ha sido clara, pero se han propuesto teorías en las que participa el metabolismo de ácidos grasos libres.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Schaffner F, Thaler H. Nonalcoholic fatty liver disease. Prog Liver Dis, 1986;8:283-298.

  2. Ludwing J, Viffiana TR, McGill DB, Ott, BJ. Non-alcoholic steatohepatitis. Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc, 1980;55:434-438.

  3. Farell GC. Drugs and steatohepatitis. Semin Liver Dis, 2002;22:185-194.

  4. Dixon JB, O´Brien PE, Bhatal PS. A wider view on diagnostic criteria of nonalcoholic steatohepatitis (reply). Gastroenterology, 2002;122:841-842.

  5. 5.Clark JM, Brancati FL, Diehl AM. Nonalcoholic fatty liver disease: the most common cause of abnormal liver enzymes in the U.S. population [abstract]. Gastroenterology, 2001;120 (Suppl):A65.

  6. Bellentani S, Saccocio G, Masutti F, et al. Prevalence of and risk factors for hepatic stetosis in northern Italy. Ann Intern Med, 2000;132:112-117.

  7. Nomura H, Kashiwagi S, Hayashi J, Kajiyama W, Tani S, Goto M. Prevalence of fatty liver in a general population of Okinawa, Japan. Jpn J Med, 1988;27:142-149.

  8. Luyckx FH, Desaive C, Thiry A et al. Liver abnormalities in severely obese subjects: effect of drastic weight loss after gastroplasty. Int J Obes Relat Metab Disord, 1998;22:222-226.

  9. Tominaga K, Kurata JH, Chen YK, et al. Prevalence of fatty liver in Japanase children and relationship to obesity: an epidemiological ultrasonographic survey. Dig Dis Sci, 1995;40:2002-2009.

  10. Franzese A, Vajro P, Argenziano A, et al. Liver involvement in obese children: ultrasonography and liver enzymes levels at diagnosis and during follow-up in an Italian population. Dig Dis Sci, 1997;42:1428-1432.

  11. Wanless IR, Lentz JS. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology, 1900;12:1106-1110.

  12. Silverman JF, Pories WJ, Caro JF. Liver pathology in diabetes mellitus and morbid obesity. Clinical, pathological, and biochemical considerations. Pathol Annual, 1989;24:275-302.

  13. Silverman JF, O´Brien KF, Long S, Leggett N, Khazanie PG, Pories WJ, Norris HT, et al. Liver pathology in morbidly obese patients with and witout diabetes. Am J Gastroenterol, 1990;85:1349-1355.

  14. Van Ness MM, Diehl AM. Is liver biopsy useful in the evaluation of patients with chronically liver enzymes?. Ann Intern Med, 1989;111:473-478.

  15. Powell EE, Cooksley WGE, Hanson R, Searle J, Halliday JW, Powell LW. The natural history of non-alcoholic steatohepatitis: A follow-up study of forty-two patients for up to 21 years. Hepatology, 1990;11:74-80.

  16. Nonokura A, Mizukami Y, Unoura M, Kobayashi K, Takeda Y, Takeda R. Clinicopathologic study of alcoholic-like liver diseasein non.alcoholics, non-alcoholic steatohepatitis and fibrosis. Gastroenterology, 1992;27:521-528.

  17. Lee RG. Non-alcoholic steatohepatitis: A study of 49 patients. Hum Pathol, 1989;20:595-598.

  18. Itho S, Yougel T, Kawogoe KE. Comparasion between non-alcoholic steatohepatitis and alcoholic hepatitis. Am J Gastroenterol, 1987;82:650-654.

  19. Bacon BR, Farahvash MJ, Janney CG, Neuschwander-Tetri BA. Nonalcoholic steatohepatitis: An expanded clinical entity. Gastroenterology, 1994;107:1103-1109.

  20. Baldrige AD, Perez-Atayde AR, Graeme-Cook F, Higgins L, Lavine JE. Idiopathic stetohepatitis in childhood a multicenter retrospective study. J Pediatry, 1995;127:700-704.

  21. Moran JR, Ghishan FK, Halter SA, Greene HL. Steatohepatitis in obese children: a cause of chronic liver dysfunction. Am J Gastroenterol, 1983;78:374-377.

  22. Dixon JB, Bhatal PS, O´Brien PE. Nonalcoholic fatty liver disease:predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese.Gastroenterology, 2001;121:91-100.

  23. Caldwell SH, Oelsner DH, Iezzoni JC, Hespennheide EE, Battle EH, Driscoll CJ. Criptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology, 1999;29:664-669.

  24. Andersen T, Christoffersen P, Gluud C. The liver in consecutive patients with morbid obesity: a clinical, morphological, and biochemical study. Int J Obes Relat Metab Disord, 1984;8:107-115.

  25. Ratziu V, Giral P, Charlotte F, Bruckert E, Thibault V, Theodorou I, Khalil L, et al. Liver fibrosis in overweight patients. Gastroenterology, 2000;118:1117-1123.

  26. García-Monzón C, Martín-Pérez E, Iacono OL, Fernández-Bermejo M, Majano PL, Apolinario A, LarraaAga E et al. Characterization of pathogenic and prognostic factors of nonalcoholic steatohepatitis associated with obesity. J Hepatol, 2000;33:716-724.

  27. Braillon A, Capron JP, Herve MA, Degott C, Quenum C. Liver in obesity. Gut, 1985;26:133-139.

  28. Kemmer NM, McKinney KH, Xiao SY, Singh H, Murray R, Abdo B, Eledrisi M, et al. High prevalence of NASH among Mexican American females with type II diabetes mellitus[abstract]. Gastroenterology, 2001;120:A117.

  29. Fong DG, Nehra V, Lindor K, Buchman AL. Metabolic and nutritional considerations in nonalcoholic fatty liver. Hetalogy, 2000;32:3-10.

  30. Araujo LMB, DeOliviera A, Nunes DS. Liver and biliary ultrasonography in diabetic and non-diabetic obese women. Diabetes Metab, 1998;24:458-462.

  31. Chituri S, Farell G, Frost L, Kriketos A, Liddle C, Samarasinghe D, George J. Serum leptin in NASH correlates with hepatic steatosis but not fibrosis: A manifestation of lipotoxicity. Hepatology, 2002;36(2):403-409.

  32. Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, Natale S, et al. Nonalcoholic fatty liver, steatohepatitis, end the metabolic syndrome. Hepatology, 2003;37(4)917-923.

  33. Rashid M, Roberts EA. Nonalcoholic steatohepatitis in children. J Pediatr Gastroenterol Nutr, 2000;30:48-53.

  34. Manton ND, Lipsett J, Moore DJ, Davidson GP, Bourne AJ, Couper RTL. Non-alcoholic steatohepatitis in children and adolescents. Med J Aust, 2000;173:476-479.

  35. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol, 1999;94:2467-2474.

  36. Diehl AM, Goodman Z, Ishah KG. Alcohol-like liver disease in nonalcoholics. A clinical and histologic comparation with alcohol-induced liver injury. Gastroenterology, 1988;95:1956-1062.

  37. Cortez-Pinto HC, Baptista A, Camilo ME, Valente A, Saragoca A, DeMoura MC. Non-alcoholic steatohepatitis: Clinico-pathological comparation with alcoholic hepatitis in ambulatory and hospitalized patients. Dig Dis Sci, 1996;41:172-179.

  38. Dile A. Nonalcoholic steatohepatitis. Semin liver Dis, 1999;19:221-229.

  39. Letteron P, Fromenty B, Terris B, Degott C, Pessayre D. Acute and chronic hepatic steatosis lead to in vivo lipid peroxidation in mice. Journal of Hepatology, 1996;24:200-208.

  40. Day CP, Yeaman SJ. The biochemistry of alcohol-induced fatty liver. Biochimica et Biophysica Acta, 1994;1215:33-48.

  41. Knobler H, Schattner A, Zhornicki T, Malnick SDH, Keter D. Sokolovskaya N, Lurie Y, Bass DD. Fatty liver-an additional and treatable feature of the insulin resistance sydrome. QJM, 1999;2:73-79.

  42. Oliver JF, Day W, Chistopher P. Non-alcoholic steatohepatitis (NASH): a disease of emerging identity and importance. Journal or Hepatology, 1998;3:495.

  43. Younossi ZM. Non-alcoholic fatty liver disease. Curr Gastroenterol Reports, 1999;1:57-61.

  44. Chituri S, Farell GC. Etiopathogenesis of nonalcoholic steatohepatitis. Semin Liver Dis, 2001;21:27-41.

  45. Saltiel AR. New perpectives into molecular patogénesis and treatment of type 2 diabetes. Cell, 2001;104:517-529.

  46. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM. Increased adipose tissue expression of tumor necrosis factor-a in human obesity and insulin resistance. J Clin Invest, 1995;95:2409-2415.

  47. Uysal KT, Wiesbrock SM, Marino MW, Hotamisligil GS. Protection from obesity-induced insulin resistence in mice lacking TNF-a function. Nature, 1997;389:610-614.

  48. Brent A, Neuschwander-Tetri, Caldwell SH. Nonalcoholic Steatohepatitis: Summary of an AASLD Single Topic Conference. Hepatology, 2003;37:1202-1219.

  49. Saxena NK, Ikeda K, Jockey DC, Friedman SL, Anania FA. Leptin in hepatic fibrosis: evidence for increased collagen production in stellate cells and lead littermates of ob/ob mice. Hepatology, 2002;35:762-771.

  50. Ikejima K, Takei Y, Honda H, Hirose M, Yoshikawa M, Zhang YJ, Lang T et al. Leptin receptor-mediated signaling regulates hepatic fibrogenesis and remodeling of extracellular matrix in the rat. Gastroenterology, 2002;122:1399-1410.

  51. Hasegawa T, Moneda M, Nakamura K, Makino I, Terano A. Plasma transforming growth factor-b1 level and efficacy of a-tocopherol in patientes witn non-alcoholic steatohepatitis: a pilot study. Aliment Pharmscol Ther, 2001;15:1667-1672.

  52. Robertson G, Leclercq I, Farrell GC. Nonalcoholic steatosis and steatohepatitis. II. Cytochrome P-450 enzymes and oxidative stress. Am J Physiol, 2001;281:G1135-G1139.

  53. Leclercq IA, Farrell GC, Field J, Bell DR, Gonzalez FJ, Robertson GR. CYP2E1 and CYP4A as microsomal catalyst of lipid peroxides in murine nonalcoholic steatohepatitis. J Clin Inves, 2000;8:1067-1075.

  54. James O, Day C. Non-alcoholic steatohepatitis: another disease of affluence. The Lancet, 1999;353:1634-1636.

  55. Marchesini G, Brizi M, Morselli-Labate A, Bianchi G, Bugianesi E, McCullough AJ, Forlani G, Melchionda N. Association of Nonalcoholic faty liver disease with insulin resistence. The American Journal of Medicine, 1999;107:450-455.

  56. Brolin RE, Bradley LJ, Taliwal RV. Unsuspected cirrhosis discoveres during obesity operations. Arch Surg, 1998;133:84-88.

  57. Abdelmalek M, Ludwing J, Lindor KD. Two cases from the spectrum of nonalcoholic steatohepatitis. J Clin Gastroenterol, 1995;20:127-130.

  58. Caldwell SH, Oelsner DH, Lezzoni J, Hespenheide EE, Batle EH, Driscoll CJ. Cryptogenic cirrhosis: Clinical characterization and risk factors for underlying disease. Hepatology, 1999;29:664-669.

  59. Kumar KS, Malet PF. Nonalcoholic Steatohepatitis. Mayo clinic Proceedings, 2000;75:733-739.

  60. James OF, Day CP. Non-alcoholic steatohepatitis (NASH): a disease of emerging identity and importance. Journal of Hepatology, 1998;29:495-501.

  61. Trauner M, Graziadei IW. Mechanisms of action and therapeutic applications of ursodeoxycholic acid in chronic liver diseases. Alimentary Pharmacology Therapeutics, 1999;13:979-995.

  62. Abdelmalek MF, Angulo P, Jorgensen RA, Silvestre PB, Lindor KD. Betaine, a promising new agent for patients with nonalcoholic steatohepatitis:results of a pilot study. Am J Gastroenterol, 2001;96:2711-2717.

  63. Gulbahar O, Karasu ZA, Ersoz G, et al. Treatment of non-alcoholic steatohepatitis with N acetylcisteine. Gastroenterology, 2000;118:A1444.

  64. Lavine JE. Vitamin E treatment of nonalcoholc steatohepatitis in children: a pilot study. J Pediatr, 2000;136:734-738.

  65. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Zoli M, Melchionda N. Metformin in non-alcoholic steatohepatitis. Lancet, 2001;358:893-894.

  66. Basaranoglu M, Acbay O, Sonsuz A. A controlled trial of gemfibrozil in the treatment on patients with nonalcoholic steatohepatitis. J Hepatol, 1999;31:384.

  67. Galli A, Crabb DW, Ceni E, Salzano R, Mello T, Svegliati-Baroni G, Ridolfi F et al. Antidiabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation in vivo and in vitro. Gastroenterology, 2002;122:1924-1940.




2020     |     www.medigraphic.com